James D. Chalmers
0000-0001-5514-7868
Publication & Citation Trends
Publications
0 total
Upper Airway Microbiome, Mucociliary Function, and Clinical Outcomes in Bronchiectasis: Data from the EMBARC-BRIDGE Study.
Cited by 2
Semantic Scholar
Pooled data from Phase II studies (AIRLEAF®, CLAIRLEAF®) of the cathepsin C (CatC, or DPP1) inhibitor BI 1291583 in bronchiectasis
Cited by 0
Semantic Scholar
Late Breaking Abstract - CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: a Phase 1 trial
Cited by 0
Semantic Scholar
Neutrophil-derived biomarkers in bronchiectasis: identifying a common therapeutic target
Cited by 10
Semantic Scholar
Subgroup analysis: AIRLEAF® Phase II study of a cathepsin C (CatC, or DPP1) inhibitor, BI 1291583, in adults with non–cystic fibrosis bronchiectasis
Cited by 0
Semantic Scholar
AIRLEAF ® –a study of verducatib as a new kind of treatment for bronchiectasis: a plain language summary
Cited by 0
Semantic Scholar
Experimental rhinovirus infection induces symptomatic and immunological exacerbation in bronchiectasis
Cited by 0
Semantic Scholar
Neutrophil elastase activity following cathepsin C (CatC, or DPP1) inhibition with BI 1291583 in people with bronchiectasis
Cited by 0
Semantic Scholar
Research Topics
Cystic Fibrosis Research Advances
(585)
Neonatal Respiratory Health Research
(316)
Chronic Obstructive Pulmonary Disease (COPD) Research
(215)
Tracheal and airway disorders
(208)
Pediatric health and respiratory diseases
(188)
Affiliations
Roche (Switzerland)
Western University
Cardiff and Vale University Health Board
NHS Lothian
University of Ulster